فوروسيميد

It is used for the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

Do not use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Furosemide Injection 5%

It is used for treatment of acute noninflammatory tissue edema.

Do not use in horses intended for food. The dosage should be adjusted to the individual's response. In refractory or severe edematous cases, the dosage may be doubled or increased by increments of 1 milligram per pound of body weight to establish the effective dose. The established effective dose should be administered once or twice daily on an intermittent daily schedule, i.e., every other day or 2 to 4 consecutive days weekly. Concurrent therapy for treatment of systemic conditions causing edema (pulmonary congestion, ascites, cardiac insufficiency) should be instituted.

Furos-A-Vet

It is used for the treatment of physiological parturient edema of the mammary gland and associated structures.

Treatment not to exceed 48 hours post-parturition. Milk taken during treatment and for 48 hours (four milkings) after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment.

Furosemide Injection 5%

Cattle (dairy)

For treatment of physiological parturient edema of the mammary gland and associated structures.

Treatment not to exceed 48 hours post-parturition. Milk taken during treatment and for 48 hours after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Lasix® Packets

It is used for the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Furosemide Injection 5%

It is used for the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Furosemide Injection 5%

Dogs and cats

For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

Furosemide Tablets

Dogs and Cats Furosemide Tablets are an effective diuretic possessing a wide therapeutic range. Pharmacologically it promotes the rapid removal of abnormally retained extracellular fluids. The rationale for the efficacious use of diuretic therapy is determined by the clinical pathology producing the edema. Furosemide Tablets are indicated for the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema. The continued use of heart stimulants, such as digitalis or its glycosides is indicated in cases of edema involving cardiac insufficiency.

FDA application 200-759

Dogs and Horses: Furosemide Injection is an effective diuretic-saluretic for use in the treatment of acute noninflammatory tissue edema in dogs and horses, and for use in the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency in the dog. In cases of edema involving cardiac insufficiency, the continued use of heart stimulants such as digitalis or its glycosides is indicated. The rationale for efficacious use of diuretic therapy in either dogs or horses is determined by the clinical pathology producing the edema.

Furosemide Injection 50 mg/mL

Dogs - Furosemide tablets are indicated for the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute non-inflammatory tissue edema. In cases of edema involving cardiac insufficiency, the continued use of heart stimulants such as digitalis or its glycosides is indicated. The rationale for efficacious use of diuretic therapy is determined by the clinical pathology producing the edema.

Furosemide Tablets

(10 mg/mL) With calibrated safety dropper FOR USE IN DOGS ONLY

Furosemide 1%Syrup

A diuretic-saluretic for prompt relief of edema.

Furosemide Syrup 1% Oral Syrup

The therapeutic efficacy of Furosemide Injection is from the activity of the intact and unaltered molecule throughout the nephron, inhibiting the reabsorption of sodium not only in the proximal and distal tubule but also in the ascending limb of the loop of Henle. The prompt onset of action is a result of the drug’s rapid absorption and a poor lipid solubility. The low lipid solubility and a rapid renal excretion minimize the possibility of its accumulation in tissues and organs or crystalluria. Furosemide has no inhibitory effect on carbonic anhydrase or aldosterone activity in the distal tubule. The drug possesses diuretic activity either in the presence of acidosis or alkalosis. 1 3 4 5 6

Furosemide Injection 50 mg/mL

Furosemide Tablets are a highly effective diuretic-saluretic which if given in excessive amounts may result in dehydration and electrolyte imbalance. Therefore, the dosage and schedule may have to be adjusted to the patient's needs. The animal should be observed for early signs of electrolyte imbalance, and corrective measures administered. Early signs of electrolyte imbalance are: increased thirst, lethargy, drowsiness or restlessness, fatigue, oliguria, gastro-intestinal disturbances and tachycardia. Special attention should be given to potassium levels. Furosemide Tablets may lower serum calcium levels and cause tetany in rare cases of animals having an existing hypocalcemic tendency. Although diabetes mellitus is a rarely reported disease in animals, active or latent diabetes mellitus may on rare occasions be exacerbated by Furosemide Tablets. While it has not been reported in animals the use of high doses of salicylates, as in rheumatic diseases, in conjunction with Furosemide Tablets may result in salicylate toxicity because of competition for renal excretory sites. Transient loss of auditory capacity has been experimentally produced in cats following intravenous injection of excessive doses of furosemide at a very rapid rate. Electrolyte balance should be monitored prior to surgery in patients receiving Furosemide Tablets. Imbalances must be corrected by administration of suitable fluid therapy. Furosemide Tablets are contraindicated in anuria. Therapy should be discontinued in cases of progressive renal disease if increasing azotemia and oliguria occur during the treatment. Sudden alterations of fluid and electrolyte imbalance in an animal with cirrhosis may precipitate hepatic coma, therefore observation during period of therapy is necessary. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved or corrected. Potassium supplementation may be necessary in cases routinely treated with potassium-depleting steroids.

FDA application 200-759

Salix® is a highly effective diuretic-saluretic which if given in excessive amounts may result in dehydration and electrolyte imbalance. Therefore, the dosage and schedule may have to be adjusted to the patient's needs. The animal should be observed for early signs of electrolyte imbalance, and corrective measures administered. Early signs of electrolyte imbalance are: increased thirst, lethargy, drowsiness or restlessness, fatigue, oliguria, gastro-intestinal disturbances and tachycardia. Special attention should be given to potassium levels. Salix® may lower serum calcium levels and cause tetany in rare cases of animals having an existing hypocalcemic tendency.10,11,12,13,14 Although diabetes mellitus is a rarely reported disease in animals, active or latent diabetes mellitus may on rare occasions be exacerbated by Salix®. While it has not been reported in animals the use of high doses of salicylates, as in rheumatic diseases, in conjunction with Salix® may result in salicylate toxicity because of competition for renal excretory sites. Transient loss of auditory capacity has been experimentally produced in cats following intravenous injection of excessive doses of Salix® at a very rapid rate.15,16,17 Electrolyte balance should be monitored prior to surgery in patients receiving Salix®. Imbalances must be corrected by administration of suitable fluid therapy. Salix® is contraindicated in anuria. Therapy should be discontinued in cases of progressive renal disease if increasing azotemia and oliguria occur during the treatment. Sudden alterations of fluid and electrolyte imbalance in an animal with cirrhosis may precipitate hepatic coma, therefore observation during period of therapy is necessary. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved or corrected. Potassium supplementation may be necessary in cases routinely treated with potassium-depleting steroids.

SALIX® (furosemide injection)

Furosemide Syrup 1% is a highly effective diureticsaluretic which if given in excessive amounts may result in dehydration and electrolyte imbalance. Therefore, the dosage and schedule may have to be adjusted to the patients' needs. The animal should be observed for early signs of electrolyte imbalance, and corrective measures administered. Early signs of electrolyte imbalance are: Increased thirst, lethargy, drowsiness or restlessness, fatigue, oliguria, gastrointestinal disturbances and tachycardia. Special attention should be given to potassium levels. Furosemide may lower serum calcium levels and cause tetany in rare cases of animals having an existing hypocalcemic tendency. 10-14 Although diabetes mellitus is a rarely reported disease in animals, active or latent diabetes mellitus may on rare occasions be exacerbated by Furosemide Syrup 1%. While it has not been reported in animals, the use of high doses of salicylates, as in rheumatic diseases, in conjunction with Furosemide Syrup 1% may result in salicylate toxicity because of competition for renal excretory sites. Electrolyte balance should be monitored prior to surgery in patients receiving Furosemide Syrup 1%. Imbalances must be corrected by administration of suitable fluid therapy. Furosemide Syrup 1% is contraindicated in anuria. Therapy should be discontinued in cases of progressive renal disease if increasing azotemia and oliguria occur during the treatment. Sudden alterations of fluid and electrolyte imbalance in an animal with cirrhosis may precipitate hepatic coma; therefore, observation during period of therapy is necessary. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved or corrected. Potassium supplementation may be necessary in cases routinely treated with potassium depleting steroids.

Furosemide Syrup 1% Oral Syrup

Animal reproductive studies have shown that furosemide may cause fetal abnormality and the drug is contraindicated in pregnant bitches, mares, and stallions at stud. Furosemide is contraindicated in anuria, furosemide hypersensitivity, hepatic coma, or during electrolytic imbalances. Monitor serum electrolytes, BUN and CO2 frequently. Monitor serum potassium levels and watch for signs of hypocalcemia. Corticosteroids cause an additive potassium-depletion effect.

Furosemide Injection 50 mg/mL

Not for use in humans. Keep out of reach of children. Keep Furosemide Tablets in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Furosemide Tablets are a highly effective diuretic and if given in excessive amounts as with any diuretic may lead to excessive diuresis which could result in electrolyte imbalance, dehydration and reduction of plasma volume enhancing the risk of circulatory collapse, thrombosis, and embolism. Therefore, the animal should be observed for early signs of fluid depletion with electrolyte imbalance, and corrective measures administered. Excessive loss of potassium in patients receiving digitalis or its glycosides may precipitate digitalis toxicity. Caution should be exercised in animals administered potassium-depleting steroids. It is important to correct potassium deficiency with dietary supplementation. Caution should be exercised in prescribing enteric-coated potassium tablets. There have been several reports in human literature, published and unpublished, concerning nonspecific small-bowel lesions consisting of stenosis, with or without ulceration, associated with the administration of enteric-coated thiazides with potassium salts. These lesions may occur with enteric-coated potassium tablets alone or when they are used with nonenteric-coated thiazides, or certain other oral diuretics. These small-bowel lesions may have caused obstruction, hemorrhage, and perforation. Surgery was frequently required, and deaths have occured. Available information tends to implicate enteric-coated potassium salts, although lesions of this type also occur spontaneously. Therefore, coated potassium-containing formulations should be administered only when indicated and should be discontinued immediately if abdominal pain, distention, nausea, vomiting, or gastro-intestinal bleeding occurs. Human patients with known sulfonamide sensitivity may show allergic reactions to Furosemide Tablets; however, these reactions have not been reported in animals. Sulfonamide diuretics have been reported to decrease arterial responsiveness to pressor amines and to enhance the effect of tubocurarine. Caution should be exercised in administering curare or its derivatives to patients undergoing therapy with Furosemide Tablets and it is advisable to discontinue Furosemide Tablets for one day prior to any elective surgery.

FDA application 200-759

Furosemide Syrup 1% is a highly effective diuretic and, as with any diuretic, if given in excessive amounts may lead to excessive diuresis that could result in electrolyte imbalance, dehydration and reduction of plasma volume, enhancing the risk of circulatory collapse, thrombosis, and embolism. Therefore, the animal should be observed for early signs of fluid depletion with electrolyte imbalance, and corrective measures administered. Excessive loss of potassium in patients receiving digitalis or its glycosides may precipitate digitalis toxicity. Caution should be exercised in animals administered potassium-depleting steroids. It is important to correct potassium deficiency with dietary supplementation. Caution should be exercised in prescribing enteric-coated potassium tablets. There have been several reports in human literature, published and unpublished, concerning nonspecific small-bowel lesions consisting of stenosis, with or without ulceration, associated with the administration of enteric-coated thiazides with potassium salts. These lesions may occur with enteric-coated potassium tablets alone or when they are used with non-enteric-coated thiazides, or certain other oral diuretics. These smallbowel lesions may have caused obstruction, hemorrhage, and perforation. Surgery was frequently required, and deaths have occurred. Available information tends to implicate enteric-coated potassium salts, although lesions of this type also occur spontaneously. Therefore, coated potassium-containing formulations should be administered only when indicated, and should be discontinued immediately if abdominal pain, distension, nausea, vomiting, or gastrointestinal bleeding occurs. Human patients with known sulfonamide sensitivity may show allergic reactions to Furosemide Syrup 1%; however, these reactions have not been reported in animals. Sulfonamide diuretics have been reported to decrease arterial responsiveness to pressor amines and to enhance the effect of tubocurarine. Caution should be exercised in administering curare or its derivatives to patients undergoing therapy with Furosemide Syrup 1% and it is advisable to discontinue Furosemide Syrup 1% for one day prior to any elective surgery. Keep Furosemide Syrup 1% in a secure location out of the reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Furosemide Syrup 1% Oral Syrup

Salix® is a highly effective diuretic and if given in excessive amounts as with any diuretic may lead to excessive diuresis which could result in electrolyte imbalance, dehydration and reduction of plasma volume enhancing the risk of circulatory collapse, thrombosis, and embolism. Therefore, the animal should be observed for early signs of fluid depletion with electrolyte imbalance, and corrective measures administered. Excessive loss of potassium in patients receiving digitalis or its glycosides may precipitate digitalis toxicity. Caution should be exercised in animals administered potassium-depleting steroids. It is important to correct potassium deficiency with dietary supplementation. Caution should be exercised in prescribing enteric-coated potassium tablets. There have been several reports in human literature, published and unpublished, concerning non-specific small-bowel lesions consisting of stenosis, with or without ulceration, associated with the administration of enteric-coated thiazides with potassium salts. These lesions may occur with enteric-coated potassium tablets alone or when they are used with nonenteric-coated thiazides, or certain other oral diuretics. These small-bowel lesions may have caused obstruction, hemorrhage, and perforation. Surgery was frequently required, and deaths have occurred. Available information tends to implicate enteric-coated potassium salts, although lesions of this type also occur spontaneously. Therefore, coated potassium-containing formulations should be administered only when indicated and should be discontinued immediately if abdominal pain, distention, nausea, vomiting, or gastro-intestinal bleeding occurs. Human patients with known sulfonamide sensitivity may show allergic reactions to Salix®; however, these reactions have not been reported in animals. Sulfonamide diuretics have been reported to decrease arterial responsiveness to pressor amines and to enhance the effect of tubocurarine. Caution should be exercised in administering curare or its derivatives to patients undergoing therapy with Salix® and it is advisable to discontinue Salix® for one day prior to any elective surgery.

SALIX® (furosemide injection)

Acute Toxicity: The following table illustrates low acute toxicity of furosemide in three different species. (Two values indicate two different studies.) LD50 of furosemide in mg/kg body weight SPECIES ORAL INTRAVENOUS Mouse 1050-1500 308 Rat 2650-4600* 680 Dog >1000 and >4640 >300 and >464 * NOTE: The lower value for the rat oral LD50 was obtained in a group of fasted animals; the higher figure is from a study performed in fed rats. Toxic doses lead to convulsions, ataxia, paralysis and collapse. Animals surviving toxic dosages may become dehydrated and depleted of electrolytes due to the massive diuresis and saluresis. Chronic Toxicity Chronic Toxicity studies with furosemide were done in a one-year study in rats and dogs. In a one-year study in rats, renal tubular degeneration occured with all doses higher than 50 mg/kg. A six-month study in dogs revealed calcification and scarring of the renal parenchyma at all doses above 10 mg/kg. Reproductive Studies Reproductive Studies were conducted in mice, rats and rabbits. Only in rabbits administered high doses (equivalent to 10 to 25 times the recommended average dose of 2 mg/kg for dogs and cats) of furosemide during the second trimester period did unexplained maternal deaths and abortions occur. The administration of furosemide is not recommended during the second trimester of pregnancy. Contact Information To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact ZyVet Animal Health Inc. at 1-877-779-9838. Additional information can be found at www.zyvetusa.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae References on file in NADA 034-621 Furosemide Tablets 12.5 mg and 50 mg Approved by FDA under ANADA # 200-759 Manufactured by: Zydus Animal Health and Investments Limited, Ahmedabad, India Distributed by: ZyVet Animal Health Inc. Pennington, NJ 08534 Rev.: 11/24

FDA application 200-759

Acute Toxicity: The following table illustrates low acute toxicity of furosemide in three different species. (Two values indicate two different studies.) LD50 of furosemide in mg/kg body weight SPECIES ORAL INTRAVENOUS Mouse 1050-1500 308 Rat 2650-4600* 680 Dog >1000 and >4640 >300 and >464 * NOTE: The lower value for the rat oral LD50 was obtained in a group of fasted animals; the higher figure is from a study performed in fed rats. Toxic doses lead to convulsions, ataxia, paralysis and collapse. Animals surviving toxic dosages may become dehydrated and depleted of electrolytes due to the massive diuresis and saluresis. Chronic Toxicity Chronic Toxicity studies with furosemide were done in a one-year study in rats and dogs. In a one-year study in rats, renal tubular degeneration occured with all doses higher than 50 mg/kg. A six-month study in dogs revealed calcification and scarring of the renal parenchyma at all doses above 10 mg/kg. Reproductive Studies Reproductive Studies were conducted in mice, rats and rabbits. Only in rabbits administered high doses (equivalent to 10 to 25 times the recommended average dose of 2 mg/kg for dogs and cats) of furosemide during the second trimester period did unexplained maternal deaths and abortions occur. The administration of furosemide is not recommended during the second trimester of pregnancy. Contact Information To report suspected adverse drug experiences, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Covetrus® North America at (855) 724-3461 or covetrus.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae References on file in NADA 034-621 Furosemide Tablets 12.5 mg and 50 mg Approved by FDA under ANADA # 200-759 Questions? (855) 724-3461 Distributed by: Covetrus® North America 400 Metro Place North Dublin, OH 43017. covetrus.com Made in India CC-FurosemideTabPI-01 REV: 0226

FDA application 200-759

Furosemide Injection is a highly effective diuretic and, if given in excessive amounts, as with any diuretic, may lead to excessive diuresis which could result in electrolyte imbalance, dehydration and reduction of plasma volume, enhancing the risk of circulatory collapse, thrombosis and embolism. Therefore, the animal should be observed for early signs of fluid depletion with electrolyte imbalance, and corrective measures administered. Excessive loss of potassium in patients receiving digitalis or its glycosides may precipitate digitalis toxicity. Caution should be exercised in animals administered potassium-depleting steroids. Correct potassium deficiency with proper dietary supplementation. If animal needs potassium supplements, use oral liquid form; do not use enteric-coated potassium tablets. The concurrent use of furosemide with some antibiotics may be inadvisable. There is evidence that the drug enhances the nephrotoxic potential of aminoglycosides, cephalosporins and polymyxins and increases the ototoxic effects of all aminoglycosides. Sulfonamide diuretics have been reported to decrease arterial responsiveness to pressor amines and to enhance the effect of tubocurarine. Caution should be exercised in administering curare or its derivatives to patients undergoing therapy with Furosemide Injection and it is advisable to discontinue Furosemide Injection for one day prior to any elective surgery. Do not use in horses intended for human consumption.

Furosemide Injection 50 mg/mL

Furosemide tablets are a highly effective diuretic and, if given in excessive amounts, as with any diuretic, may lead to excessive diuresis which could result in electrolyte imbalance, dehydration and reduction of plasma volume, enhancing the risk of circulatory collapse, thrombosis and embolism. Therefore, the animal should be observed for early signs of fluid depletion with electrolyte imbalance, and corrective measures administered. Excessive loss of potassium in patients receiving digitalis or its glycosides may precipitate digitalis toxicity. Caution should be exercised in animals administered potassium-depleting steroids. Correct potassium deficiency with proper dietary supplementation. If animal needs potassium supplements, use oral liquid form, do not use enteric-coated potassium tablets. The concurrent use of furosemide with some antibiotics may be inadvisable. There is evidence that the drug enhances the nephrotoxic potential of aminoglycosides, cephalosporins and polymyxins and increases the ototoxic effects of all aminoglycosides. Sulfonamide diuretics have been reported to decrease arterial responsiveness to pressor amines and to enhance the effect of tubocurarine. Caution should be exercised in administering curare or its derivatives to patients undergoing therapy with Furosemide tablets and it is advisable to discontinue Furosemide tablets for one day prior to any elective surgery.

Furosemide Tablets

To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact First Priority, Inc. at (800) 650-4899 or www.prioritycare. com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae

Furosemide Syrup 1 % (10 mg/mL)

The drug is administered intramuscularly or intravenously at a dosage of 12.5 to 25 milligrams per 10 pounds of body weight; once or twice daily after a 6- to 8-hour interval. The dosage should be adjusted to the individual animal's response. In refractory or severe edematous cases the dosage may be doubled or increased by increments of 1 milligram per pound of body weight to establish the effective dose. The established effective dose should be administered once or twice daily on an intermittent daily schedule. Diuretic therapy should be discontinued after reduction of edema, or when necessary, maintained after determining a programmed dosage schedule to prevent recurrence.

Intravenous, Intramuscular

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Salix®

The drug is administered intramuscularly or intravenously at a dosage of 12.5 to 25 milligrams per 10 pounds of body weight; once or twice daily after a 6- to 8-hour interval. Indications: It is used for the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

Intravenous, Intramuscular

The dosage should be adjusted to the individual animal's response. In refractory or severe edematous cases the dosage may be doubled or increased by increments of 1 milligram per pound of body weight to establish the effective dose. The established effective dose should be administered once or twice daily on an intermittent daily schedule. Diuretic therapy should be discontinued after reduction of edema, or when necessary, maintained after determining a programmed dosage schedule to prevent recurrence.

Disal®

1.25 to 2.5 mg per pound (/lb) body weight once or twice daily, intramuscularly or intravenously.

Intravenous, Intramuscular

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Furosemide Injection 5%

1 to 2 milligrams per pound of body weight, once or twice daily.

Oral

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Furosemide Syrup 1%

Administer intramuscularly or intravenously at 0.5 milligram per pound of body weight (1.0 milligram per kilogram); once or twice daily at 6- to 8-hour intervals.

Intramuscular, Intravenous

Do not use in horses intended for food. The dosage should be adjusted to the individual's response. In refractory or severe edematous cases, the dosage may be doubled or increased by increments of 1 milligram per pound of body weight to establish the effective dose. The established effective dose should be administered once or twice daily on an intermittent daily schedule, i.e., every other day or 2 to 4 consecutive days weekly. Concurrent therapy for treatment of systemic conditions causing edema (pulmonary congestion, ascites, cardiac insufficiency) should be instituted.

Disal® Injection

Administer intramuscularly or intravenously at 250 to 500 milligrams per animal once or twice daily.

Intravenous, Intramuscular

Do not use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Furosemide Injection 5%

0.5 mg/lb body weight once or twice daily, intramuscularly or intravenously.

Intravenous, Intramuscular

Do not use in horses intended for human consumption. The dosage should be adjusted to the individual animal's response. In refractory or severe edematous cases the dosage may be doubled or increased by increments of 0.5 milligram per pound of body weight to establish the effective dose. The established effective dose should be administered once or twice daily on an intermittent daily schedule. Diuretic therapy should be discontinued after reduction of edema, or when necessary, maintained after determining a programmed dosage schedule to prevent recurrence.

Disal®

250 to 500 mg/animal once or twice daily, intramuscularly or intravenously.

Intravenous, Intramuscular

Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Salix®

The drug is administered intramuscularly or intravenously at a dosage of 500 milligrams per animal once daily or 250 milligrams per animal twice daily at 12-hour intervals, treatment not to exceed 48 hours post parturition.

Intravenous, Intramuscular

Milk taken during treatment and for 48 hours (four milkings) after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment. The drug if given in excessive amounts may result in dehydration and electrolyte imbalance. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Salix®

500 milligrams per animal once daily, intramuscularly or intravenously; or 250 milligrams per animal twice daily at 12-hour intervals, intramuscularly or intravenously.

Intravenous, Intramuscular

Treatment not to exceed 48 hours post-parturition. Milk taken during treatment and for 48 hours (four milkings) after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment.

Furosemide Injection 5%

Cattle (dairy)

1 to 2 milligram per pound body weight using powder, or one 2-gram bolus per animal, per day.

Oral

Treatment not to exceed 48 hours post-parturition. Milk taken during treatment and for 48 hours after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Lasix® Packets

The drug is administered intramuscularly or intravenously at a dosage of 12.5 to 25 milligrams per 10 pounds of body weight; once or twice daily after a 6- to 8-hour interval. The lower dosage is suggested for cats. The dosage should be adjusted to the individual animal's response. In refractory or severe edematous cases the dosage may be doubled or increased by increments of 1 milligram per pound of body weight to establish the effective dose. The established effective dose should be administered once or twice daily on an intermittent daily schedule. Diuretic therapy should be discontinued after reduction of edema, or when necessary, maintained after determining a programmed dosage schedule to prevent recurrence.

Intravenous, Intramuscular

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Salix®

1.25 to 2.5 mg per pound (/lb) body weight once or twice daily, intramuscularly or intravenously.

Intravenous, Intramuscular

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Furosemide Injection 5%

1 to 2 milligrams per pound of body weight, once or twice daily.

Oral

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Salix® Tablets

Dogs and cats

1 to 2 mg/lb body weight (approximately 2.5 to 5 mg/kg). The lower dosage is suggested for cats. Administer once or twice daily at 6 to 8 hour intervals either orally, intravenously, or intramuscularly.

Oral

Furosemide Tablets

The usual dose of Furosemide Syrup 1 % is 1 to 2 mg/lb body weight (approximately 2.5 to 5 mg/kg). Administer once or twice daily at 6- to 8-hour intervals orally. A prompt diuresis usually ensues from the initial treatment. Diuresis may be initiated by the parenteral administration of furosemide injection and then maintained by oral administration. The dosage should be adjusted to the individual's response. In severe edematous or refractory cases, the dose may be doubled or increased by increments of 1 mg/lb body weight. The established effective dose should be administered once or twice daily. The daily schedule of administration can be timed to control the period of micturition of the convenience of the client or veterinarian. Mobilization of the edema may be most efficiently and safely accomplished by utilizing an intermittent daily dosage schedule, i.e., every other day or 2 to 4 consecutive days weekly. Diuretic therapy should be discontinued after reduction of the edema, or maintained after determining a carefully programmed dosage schedule to prevent recurrence of edema. For long-term treatment, the dose can generally be lowered after the edema has once been reduced. Re-examination and consultations with client will enhance the establishment of a satisfactorily programmed dosage schedule. Clinical examination and serum BUN, CO2 and electrolyte determinations should be performed during the early period of therapy and periodically thereafter, especially in refractory cases. Abnormalities should be corrected or the drug temporarily withdrawn. DOSAGE ORAL: DOG-Syrup 1 % One (1) to two (2) mL (10 to 20 mg furosemide) per 10 lb body weight (approximately 2.5 to 5 mg/kg). Administered once or twice daily, permitting a 6- to 8-hour interval between treatments. In refractory or severe edematous cases, the dosage may be doubled or increased by increments of 1 mg/lb body weight as recommended in preceding paragraphs, "DOSAGE AND ADMINISTRATION."

ORAL

Furosemide Syrup 1% Oral Syrup

Dogs—Administer intravenously or intramuscularly 0.25 to 0.50 mL per 10 pounds body weight once or twice daily at 6 to 8 hour intervals. The dosage should be adjusted to the individual’s response. In severe edematous or refractory cases, the dose may be doubled or increased by increments of 1.0 mg per pound of body weight. The established effective dose should be administered once or twice daily. Discontinue diuretic therapy with Furosemide Injection, 50 mg/mL after initiation of acute fluid mobilization or stabilization of patient; when necessary Furosemide Tablets may be used for maintenance therapy (see Furosemide Tablets insert for details). Do not exceed treatment with Furosemide Injection, 50 mg/mL for more than 3 days. The daily schedule of administration can be timed to control the period of micturition for the convenience of the client or veterinarian. Mobilization of the edema may be most efficiently and safely accomplished by utilizing an intermittent daily dose schedule, i.e., every other day or 2 to 4 consecutive days weekly. Horses—The usual parenteral dosage of furosemide in horses is approximately 0.5 mg/lb body weight (1.0 mg/kg). See dosage schedule below. A prompt diuresis usually ensues from the initial treatment. Administer once or twice daily at 6 to 8 hour intervals either intravenously or intramuscularly until desired results are achieved. The dosage should be adjusted to the individual’s response. In severe edematous or refractory cases, the dose may be doubled or increased by increments of 0.5 mg per pound of body weight. The established effective dose should be administered once or twice daily. The daily schedule of administration can be timed to control the period of micturition for the convenience of the client or veterinarian. Mobilization of the edema may be most efficiently and safely accomplished by utilizing an intermittent daily dose schedule, i.e., every other day or 2 to 4 consecutive days weekly.

INTRAMUSCULAR, INTRAVENOUS

Furosemide Injection 50 mg/mL

The usual oral dosage of furosemide tablets is 1 to 2 mg/lb body weight (approximately 2.5 to 5 mg/kg). A prompt diuresis usually ensues from the initial treatment. Administer orally once or twice daily at 6 to 8 hour intervals. The dosage should be adjusted to the individual's response. In severe edematous or refractory cases, the dose may be doubled or increased by increments of 1.0 mg per pound of body weight. The established effective dose should be administered once or twice daily. The daily schedule of administration can be timed to control the period of micturition for the convenience of the client or veterinarian. Mobilization of the edema may be most efficiently and safely accomplished by utilizing an intermittent daily dose schedule, i.e., every other day or 2 to 4 consecutive days weekly. Diuretic therapy should be discontinued after reduction of the edema, or maintained after determining a carefully programmed dosage schedule to prevent recurrence of edema. For long-term treatment, the dose can generally be lowered after the edema has once been reduced. Re-examination and consultations with the client will enhance the establishment of a satisfactorily programmed dosage schedule. Clinical examination and serum BUN, CO2 and electrolyte determinations should be performed during the early period of therapy and periodically thereafter, especially in refractory cases. Abnormalities should be corrected or the drug temporarily withdrawn. Dosage: Oral Dog: One-half to one 50 mg scored tablet per 25 pounds body weight. One 12.5 mg scored tablet per 5 to 10 pounds body weight. Administer once or twice daily, permitting a 6- to 8-hour interval between treatments. In refractory or severe edematous cases, the dosage may be doubled or increased by increments of 1 mg per pound body weight as recommended in preceding paragraphs, "Dosage and administration".

ORAL

Furosemide Tablets

The usual dosage of furosemide is 1 to 2 mg/lb. body weight (approximately 2.5 to 5 mg/kg). The lower dosage is suggested for cats. Administer once or twice daily at 6 to 8 hour intervals either orally, intravenously, or intramuscularly. A prompt diuresis usually ensues from the initial treatment. Diuresis may be initiated by the parenteral administration of furosemide injection and then maintained by oral administration. The dosage should be adjusted to the individual's response. In severe edematous or refractory cases, the dose may be doubled or increased by increments of 1 mg per pound body weight. The established effective dose should be administered once or twice daily. The daily schedule of administration can be timed to control the period of micturition for the convenience of the client or veterinarian. Mobilization of the edema may be most efficiently and safely accomplished by utilizing an intermittent daily dosage schedule, i.e. every other day or 2 to 4 consecutive days weekly. Diuretic therapy should be discontinued after reduction of the edema, or maintained after determining a carefully programmed dosage schedule to prevent recurrence of edema. For long-term treatment, the dose can generally be lowered after the edema has once been reduced. Re-examination and consultations with client will enhance the establishment of a satisfactorily programmed dosage schedule. Clinical examination and serum BUN, CO2 and electrolyte determinations should be performed during the early period of therapy and periodically thereafter, especially in refractory cases. Abnormalities should be corrected or the drug temporarily withdrawn.

ORAL

FDA application 200-759

The usual dosage of Salix® is 1 to 2 mg/lb. body weight (approximately 2.5 to 5 mg/kg). The lower dosage is suggested for cats. Administer once or twice daily at 6 to 8 hour intervals either orally, intravenously, or intramuscularly. A prompt diuresis usually ensues from the initial treatment. Diuresis may be initiated by the parenteral administration of Salix® Injection and then maintained by oral administration. The dosage should be adjusted to the individual's response. In severe edematous or refractory cases, the dose may be doubled or increased by increments of 1 mg per pound body weight. The established effective dose should be administered once or twice daily. The daily schedule of administration can be timed to control the period of micturition for the convenience of the client or veterinarian. Mobilization of the edema may be most efficiently and safely accomplished by utilizing an intermittent daily dosage schedule, i.e., every other day or 2 to 4 consecutive days weekly. Diuretic therapy should be discontinued after reduction of the edema, or maintained after determining a carefully programmed dosage schedule to prevent recurrence of edema. For long-term treatment, the dose can generally be lowered after the edema has once been reduced. Re-examination and consultations with client will enhance the establishment of a satisfactorily programmed dosage schedule. Clinical examination and serum BUN, CO2 and electrolyte determinations should be performed during the early period of therapy and periodically thereafter, especially in refractory cases. Abnormalities should be corrected or the drug temporarily withdrawn.

INTRAMUSCULAR, INTRAVENOUS

SALIX® (furosemide injection)

Horses: Administer IV or IM once or twice daily at 6-8 hour intervals until desired results are achieved. Body Weight (lbs) Furosemide injection (50 mg/mL) 500 4.6 mL 600 5.5 mL 700 6.4 mL 800 7.3 mL 900 8.2 mL 1000 9.1 mL 1100 10.0 mL 1200 10.9 mL Diuretic therapy for both dogs and horses should be discontinued after reduction of the edema, or maintained after determining a carefully programmed dosage schedule to prevent recurrence of edema. For long-term treatment, the dose can generally be lowered after the edema has once been reduced. Re-examination and consultations with the client will enhance the establishment of a satisfactorily programmed dosage schedule. Clinical examination and serum BUN, CO2 and electrolyte determinations should be performed during the early period of therapy and periodically thereafter, especially in refractory cases. Abnormalities should be corrected or the drug temporarily withdrawn.

INTRAMUSCULAR, INTRAVENOUS

Furosemide Injection 50 mg/mL